Published in Hepatitis Weekly, July 10th, 2006
"With CLD respond poorly to standard HBV vaccine given as sequential 20 mcg IM shots because of an overall impaired immune response. Many of these patients go on to liver transplantation and are at risk of acquiring recurrent or de novo HBV infection," wrote A. Aziz and colleagues, Loyola University.
They stated their goal was "to evaluate the efficacy and safety of high-dose (80 mcg) IM HBV vaccination in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.